SUTRO BIOPHARMA, INC. Capital Expenditures
SUTRO BIOPHARMA, INC. (STRO) reported Capital Expenditures of $763.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2020-05-11
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2020-03-31 was $763.00K, a 176.45% increase year-over-year.
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2019-09-30 was $667.00K, a 85.79% increase year-over-year.
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2019-06-30 was $489.00K, a 1258.33% increase year-over-year.
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for the quarter ending 2019-03-31 was $276.00K, a 24.18% decline year-over-year.
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2018 was $1.56M, a 53.05% decline from fiscal 2017.
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2017 was $3.32M, a 24.53% decline from fiscal 2016.
- SUTRO BIOPHARMA, INC. payments to acquire property, plant, and equipment for fiscal 2016 was $4.39M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2020-03-31 | $763.00K 10-Q · filed 2020-05-11 | |||
| 2019-09-30 | $667.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $1.16M derived: sum of 2 quarters · filed 2019-11-08 | $1.43M 10-Q · filed 2019-11-08 | $2.23M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-06-30 | $489.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $765.00K 10-Q · filed 2019-08-14 | $1.56M derived: sum of 3 quarters · filed 2020-05-11 | $1.92M derived: sum of 4 quarters · filed 2020-05-11 |
| 2019-03-31 | $276.00K 10-Q · filed 2020-05-11 | $1.07M derived: sum of 2 quarters · filed 2020-05-11 | $1.43M derived: sum of 3 quarters · filed 2020-05-11 | $1.47M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $798.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.16M derived: sum of 2 quarters · filed 2019-11-08 | $1.19M derived: sum of 3 quarters · filed 2019-11-08 | $1.56M 10-K · filed 2019-04-01 |
| 2018-09-30 | $359.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $395.00K derived: sum of 2 quarters · filed 2019-11-08 | $759.00K 10-Q · filed 2019-11-08 | $1.42M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $400.00K 10-Q · filed 2019-08-14 | $1.06M derived: sum of 3 quarters · filed 2019-08-14 | |
| 2018-03-31 | $364.00K 10-Q · filed 2019-05-15 | $1.02M derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $657.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $3.32M 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $2.66M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $4.39M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |